[Form 4] Septerna, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Septerna, Inc. reported a compensatory stock option grant to its Chief Medical Officer, Kim Jae B. The award is a stock option to purchase 55,000 shares of common stock at an exercise price of $11.70 per share. The option grant date is shown as 08/07/2025 and the option expires on 08/06/2035. The option vests in a two-step schedule: 2/48ths of the shares become exercisable on October 1, 2025, with the remaining shares vesting in 46 substantially equal monthly installments thereafter, subject to continuous service. The shares are reported as directly owned following the transaction. This filing documents the terms and vesting timetable of the derivative award to an executive officer.

Positive

• 55,000-share stock option grant is explicitly documented, including exercise price and expiration date
• Vesting schedule is clearly defined: 2/48ths on October 1, 2025 then 46 monthly installments, providing transparency on service conditions

Negative

• None.

Insights

Securities Analyst

TL;DR: Routine officer equity grant: 55,000 options at $11.70 with a standard service-based vesting schedule, moderate duration to expiration.

The reported transaction is a conventional option award to an executive officer. Key facts are a 55,000-share option grant with an $11.70 exercise price and an August 6, 2035 expiration. Vesting begins with a small initial tranche on October 1, 2025 and continues monthly, tying realization to continued service. For investors, this is primarily a compensation disclosure; it does not itself change outstanding common shares until options are exercised.

Corporate Governance Expert

TL;DR: Governance disclosure shows a service-contingent equity award to a named officer with clear vesting terms and direct ownership reporting.

The form discloses material grant terms transparently: option quantity, $11.70 exercise price, vesting schedule (2/48ths at first vest date then monthly installments), and a defined expiration date. The reporting person is identified as the Chief Medical Officer and the ownership form is direct. This meets standard Section 16 reporting expectations for executive compensation events; the filing does not indicate any atypical acceleration provisions or third-party arrangements.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kim Jae B.

(Last) (First) (Middle)

C/O SEPTERNA, INC.

250 EAST GRAND AVENUE

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Septerna, Inc. [ SEPN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
08/07/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$11.7	08/07/2025		A		55,000		(1)	08/06/2035	Common Stock	55,000	$0	55,000	D

Explanation of Responses:

1. 2/48th of the shares subject to such option shall vest and become exercisable on October 1, 2025 and the remaining shares subject to the option shall vest in 46 substantially equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.

	/s/ Ran Xiao, Attorney-in-Fact	08/11/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Septerna (SEPN) disclose in this Form 4?

The company disclosed a stock option grant to the Chief Medical Officer for 55,000 shares with an exercise price of $11.70 per share.

When was the transaction dated for the SEPN option grant?

The transaction date reported is 08/07/2025.

What is the vesting schedule for the options reported on SEPN Form 4?

Vesting begins with 2/48ths of the option shares on October 1, 2025, with the remaining shares vesting in 46 substantially equal monthly installments thereafter, contingent on continuous service.

When do the options expire?

The option expiration date is listed as 08/06/2035.

How many shares are beneficially owned following the transaction?

The filing reports 55,000 derivative securities beneficially owned following the reported transaction.

What is the reporting person's role at Septerna?

The reporting person, Kim Jae B., is identified as the company's Chief Medical Officer.